Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 3/20 | 0.49 |
| ▸ | CNR2 | P34972 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31370647 | 0.94 | LMNA (0.56) | LMNABCHECNR2CA12CA1 | |
| SCHEMBL30724437 | 0.91 | BCHE (0.48) | LMNABCHECNR2CA12CA1 | |
| SCHEMBL27347363 | 0.91 | BCHE (0.48) | LMNABCHECNR2CA12CA1 | |
| SCHEMBL30724440 | 0.91 | BCHE (0.48) | LMNABCHECNR2CA12CA1 | |
| SCHEMBL30724434 | 0.91 | BCHE (0.48) | LMNABCHECNR2CA12CA1 | |
| SCHEMBL27347355 | 0.91 | BCHE (0.48) | LMNABCHECNR2CA12CA1 | |
| SCHEMBL27076601 | 0.91 | LMNA (0.55) | LMNACA12CA1CA2CA9 | |
| SCHEMBL30789048 | 0.91 | LMNA (0.55) | LMNACA12CA1CA2CA9 | |
| SCHEMBL29162892 | 0.90 | LMNA (0.54) | LMNACA12CA1CA2CA9 | |
| SCHEMBL30776081 | 0.90 | LMNA (0.54) | LMNACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339566-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | UNIV ANTWERPEN (BE) | 2025-11-06 | — | — | US | disclosed |
| EP-4531932-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Universiteit Antwerpen (BE) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023233023-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | UNIVERSITEIT ANTWERPEN (BE) | 2023-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339566-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FIBP, FGF1, FGFR1 | LMNA 1367/4885BCHE 4065/4885CNR2 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.